← Back to feed

2 sourcesTracking since 21 Sept, 15:05

<a href="https://www.fiercebiotech.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

ShareX WhatsApp Facebook LinkedIn

Novo Nordisk

Chronological coverage

21 September
Latest21 Sept, 15:23
<a href="https://www.fiercepharma.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”
Fierce Pharma•James Waldron, Fraiser Kansteiner
First seen21 Sept, 15:05
<a href="https://www.fiercebiotech.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”
Fierce Biotech•James Waldron, Fraiser Kansteiner